CLRB - Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today? | Benzinga
Cellectar Biosciences Inc (NASDAQ: CLRB) announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients that have received at least two prior lines of therapy.
Waldenström macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow.
CLOVER WaM is the largest study to ...